Compare Gilead Sciences, Inc. (GILD) vs Paychex, Inc. (PAYX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Paychex, Inc. — how do they compare? Gilead Sciences, Inc. trades at $135 (market cap $164.99B), while Paychex, Inc. trades at $120.92 (market cap $43.10B). The key difference: Gilead Sciences, Inc. is far larger — about 3.8× Paychex, Inc.'s market cap, and Paychex, Inc. pays the higher dividend (3.93%). Which is the better fit depends on your goals.
| GILD | PAYX | |
|---|---|---|
Market Cap | $164.99B | $43.10B |
Sector | Health | Industrials |
52-Week High | $155.80 | $140.81 |
52-Week Low | $110.56 | $85.57 |
Enterprise Value | $188.06B | $46.59B |
Dividend Yield | 2.47% | 3.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Paychex (PAYX) trades at $120.04, down slightly by 0.07% on the day, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.32 exceeding the $1.31 estimate. Revenue grew to $5.57 billion in 2025, though net income margin dipped to 27.03%. Recent news highlights expansion of its WISE platform and steady small business employment trends, supporting growth prospects.
The outlook remains positive given consistent earnings outperformance and strategic initiatives, but risks include elevated valuation ratios and potential economic sensitivity. Analyst consensus is mixed with a hold-heavy rating, and the current price sits above the $114.50 target, suggesting limited near-term upside. Dividend payments provide income support, yet investors should weigh growth against premium multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
